LP
BNTC icon

Longaeva Partners’s Benitec Biopharma BNTC Stock Holding History

Longaeva Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Sell
14,874
-110,126
-88% -$1.31M ﹤0.01% 336
2026
Q1 		$1.33M Sell
125,000
-165,000
-57% -$1.91M 0.05% 165
2025
Q4 		$3.91M Buy
290,000
+252,463
+673% +$3.49M 0.33% 69
2025
Q3 		$527K Sell
37,537
-14,460
-28% -$185K 0.08% 68
2025
Q2 		$608K Sell
51,997
-28,003
-35% -$392K 0.12% 48
2025
Q1 		$1.04M Buy
+80,000
New +$968K 0.59% 17

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Longaeva Partners's BNTC Position: Q2 2026 in Review

Longaeva Partners reduced its Benitec Biopharma (BNTC) stake by 88% in Q2 2026, selling an estimated $1.31M and leaving 14,874 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #336.

Longaeva Partners first reported a position in BNTC in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.91M in Q4 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Longaeva Partners held 14,874 shares of Benitec Biopharma worth $199K as of Q2 2026.
  • Longaeva Partners sold 110,126 Benitec Biopharma shares in Q2 2026, an estimated $1.31M.
  • Benitec Biopharma made up ﹤0.01% of Longaeva Partners's portfolio in Q2 2026, its #336 holding.
  • Longaeva Partners first reported a position in Benitec Biopharma in Q1 2025 and has held it in 6 quarters since.
  • Longaeva Partners's Benitec Biopharma position peaked at $3.91M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.